Congress

14:00 - 14:20
A visão do Judiciário

BARBARA AREIAS REZENDE

SP Speaker

14:20 - 14:30
Discussão

14:30 - 14:50
A visão da Indústria Farmacêutica

14:50 - 15:00
Discussão

15:00 - 15:20
A visão da CONITEC

15:20 - 15:30
Discussão

15:30 - 15:50
A visão da Saúde Suplementar

15:50 - 16:00
Discussão

16:30 - 16:50
Multidisciplinary care in MS: impact in the quality of life

LILIANA PATRUCCO

Speaker

16:50 - 17:00
Discussion

17:00 - 17:20
Physical Exercise in MS Rehabilitation: Progress, Key Learnings, and Ongoing Challenges

CINTIA RAMARI FERREIRA

UBATUBA / SP Speaker

17:20 - 17:30
Discussion

17:30 - 17:50
PROMS and Multiact initiatives: perspectives and potential

GIAMPAOLO BRICHETTO

Speaker

17:50 - 18:00
Discussion

08:30 - 08:50
ACTRIMS "Impact of the new MS criteria in North America"

DANIEL ONTANEDA

Speaker

08:50 - 09:00
Discussion

09:00 - 09:20
BCTRIMS "MS and NMOSD Databases in Brazil"

HENRY KOITI SATO

CURITIBA / PR Speaker

09:20 - 09:30
Discussion

09:30 - 09:50
PACTRIMS "NMOSD in India: Epidemiology and Clinical Features"

LEKHA PANDIT

Speaker

09:50 - 10:00
Discussion

10:00 - 10:20
LACTRIMS "NMO and Infections in Latin America"

10:20 - 10:30
Discussion

10:30 - 10:50
ECTRIMS "Current Status of MS Treatment in Europe"

HANS-PETER HARTUNG

Speaker

10:50 - 11:00
Discussion

11:30 - 12:10
Rationale and Perspectives on the Future of NMO

JACQUELINE PALACE

Speaker

14:10 - 14:30
Chronic Active Lesions - from diagnosis to prognosis

DANIEL ONTANEDA

Speaker

14:30 - 14:40
Discussion

14:40 - 15:00
The road to remyelination

MILENA SALES PITOMBEIRA

FORTALEZA / CE Speaker

15:00 - 15:10
Discussion

15:10 - 15:30
Is it RRMS with PIRA or SPMS?

HANS-PETER HARTUNG

Speaker

15:30 - 15:40
Discussion

15:40 - 15:47
Platform presentation 03

15:47 - 15:50
Discussion

16:20 - 16:40
Regional considerations in the differential diagnosis of MS

LILIANA PATRUCCO

Speaker

16:40 - 16:50
Discussion

16:50 - 17:10
Updated evidence in DMTs discontinuation and de-escalation in MS

TARSO ADONI

SÃO PAULO / SP Speaker

17:10 - 17:20
Discussion

17:20 - 17:27
Platform presentation 04

17:27 - 17:30
Discussion

08:30 - 08:50
Gaps in NMOSD research

MARCELO MATIELLO

Speaker

08:50 - 09:00
Discussion

09:00 - 09:20
The Global Impact of Race on NMOSD: Epidemiology and Disparities

MARCO LANA PEIXOTO

BELO HORIZONTE / MG Speaker

09:20 - 09:30
Discussion

09:30 - 09:50
NMOSD and its Outcome in Thai and Other Asian Populations

SASITORN SIRITHO

Speaker

09:50 - 10:00
Discussion

10:00 - 10:07
Platform presentation 7 ( NMOSD 7)

10:07 - 10:10
Discussion

10:40 - 11:00
The Growing Impact of Treatment on NMOSD Outcomes

LEKHA PANDIT

Speaker

11:00 - 11:10
Discussion

11:10 - 11:30
Cell therapy and tolerization in NMOSD

11:30 - 11:40
Discussion

11:40 - 11:47
Platform presentation 8

11:47 - 11:50
Discussion

16:20 - 16:40
Autoimmune encephalitis: treatment insights from the Brazilian Cohort (BRAIN)

16:40 - 16:50
Discussion

16:50 - 17:10
Combined Central and Peripheral Demyelination: New Insights in Diagnosis, and Treatment

OSVALDO NASCIMENTO

RIO DE JANEIRO / RJ Speaker

17:10 - 17:20
Discussion

17:20 - 17:40
NMOSD Care from the Patient’s Perspective: What Every Doctor Should Know

DANIELE AMERICANO

RJ Speaker

17:40 - 17:50
Discussion

08:00 - 08:20
Normal tissue appearing damage in NMO: what advanced MRI can add?

MATEUS BOAVENTURA DE OLIVEIRA

SP Speaker

08:20 - 08:30
Discussion

08:30 - 08:50
Central vein sign and paramagnetic rim lesion evaluation in clinical practice: Application and pitfalls

DANIEL ONTANEDA

Speaker

08:50 - 09:00
Discussion

09:00 - 09:20
IA application in demylinating disorders

FERNANDA CRISTINA RUEDA LOPES

RIO DE JANEIRO / RJ Speaker

09:20 - 09:30
Discussion

09:30 - 09:50
Detection of infratentorial and spinal cord lesions: challenges and implications in MS

09:50 - 10:00
Discussion

10:30 - 10:50
MRI predictors of the differential diagnosis of pediatric MS and MOGAD - how to apply the evidence from research in clinical practice

10:50 - 11:00
Discussion

11:00 - 11:20
Experience with the use of high-efficacy DMTs in pediatric patients with MS. Are they really superior to 1st line DMTs?

SILVIA TENEMBAUM

Speaker

11:20 - 11:30
Discussion

11:30 - 11:50
Real life challenges in the diagnosis and treatment of pediatric NMOSD

11:50 - 12:00
Discussion